Looking for a new investing play when it comes to the COVID-19 stocks?
Jim Cramer, on Bull Market Fantasy, discussed Fluidigm.
The company, which is publicly traded, currently trades around $7 a share. Year-to-date, it's up over 111%.
The company was getting a boost in trading on Monday following the news last week that its COVID-19 saliva test was selected by the Trump Administration to be used in a U.S. federal program at testing sites in Texas.
The first community to offer the saliva tests will be Waco, Texas.
Back on Oct. 8, Fluidigm announced, "announced a program to expand the availability of COVID-19 tests for colleges and universities. The Fluidigm COVID-19 Campus Safeguard Program will provide millions of noninvasive, saliva-based tests for the SARS-CoV-2 virus to qualifying institutions at a cost as low as per test. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the high-throughput Fluidigm Biomark™ HD system features an integrated testing platform and a reliable supply chain and can be easily combined with commonly available automation platforms," the company said in a press release.
"Fluidigm has received Emergency Use Authorization (EUA) from the (FDA) for the Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARSCoV2 virus. The assay does not require collection via invasive nasopharyngeal swab. The company’s submission to the FDA demonstrated 100 percent agreement between saliva results from the Advanta Dx SARS-CoV-2 RT-PCR Assay and results from paired nasopharyngeal samples tested with authorized assays," the company continued.
Watch the video above for more from Jim Cramer.